🎉 M&A multiples are live!
Check it out!

Dishman Carbogen Amics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Dishman Carbogen Amics and similar public comparables like Piramal Pharma, Suven Pharma, and Syngene International.

Dishman Carbogen Amics Overview

About Dishman Carbogen Amics

Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.


Founded

2007

HQ

India
Employees

1.1K+

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$630M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Dishman Carbogen Amics Financials

Dishman Carbogen Amics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Dishman Carbogen Amics achieved revenue of $293M and an EBITDA of $34.7M.

Dishman Carbogen Amics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Dishman Carbogen Amics valuation multiples based on analyst estimates

Dishman Carbogen Amics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $277M $293M XXX XXX XXX
Gross Profit $193M $217M XXX XXX XXX
Gross Margin 70% 74% XXX XXX XXX
EBITDA $34.6M $34.7M XXX XXX XXX
EBITDA Margin 12% 12% XXX XXX XXX
Net Profit $2.1M -$3.4M XXX XXX XXX
Net Margin 1% -1% XXX XXX XXX
Net Debt $151M $194M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Dishman Carbogen Amics Stock Performance

As of March 19, 2025, Dishman Carbogen Amics's stock price is INR 217 (or $2).

Dishman Carbogen Amics has current market cap of INR 34.0B (or $391M), and EV of INR 54.8B (or $630M).

See Dishman Carbogen Amics trading valuation data

Dishman Carbogen Amics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$630M $391M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Dishman Carbogen Amics Valuation Multiples

As of March 19, 2025, Dishman Carbogen Amics has market cap of $391M and EV of $630M.

Dishman Carbogen Amics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Dishman Carbogen Amics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Dishman Carbogen Amics and 10K+ public comps

Dishman Carbogen Amics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $630M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Dishman Carbogen Amics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Dishman Carbogen Amics Valuation Multiples

Dishman Carbogen Amics's NTM/LTM revenue growth is n/a

Dishman Carbogen Amics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Dishman Carbogen Amics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Dishman Carbogen Amics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Dishman Carbogen Amics and other 10K+ public comps

Dishman Carbogen Amics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 5% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 0% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 1% XXX XXX XXX XXX
G&A Expenses to Revenue 4% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 76% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Dishman Carbogen Amics Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Suven Pharma XXX XXX XXX XXX XXX XXX
Piramal Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Dishman Carbogen Amics M&A and Investment Activity

Dishman Carbogen Amics acquired  XXX companies to date.

Last acquisition by Dishman Carbogen Amics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Dishman Carbogen Amics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Dishman Carbogen Amics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Dishman Carbogen Amics

When was Dishman Carbogen Amics founded? Dishman Carbogen Amics was founded in 2007.
Where is Dishman Carbogen Amics headquartered? Dishman Carbogen Amics is headquartered in India.
How many employees does Dishman Carbogen Amics have? As of today, Dishman Carbogen Amics has 1.1K+ employees.
Is Dishman Carbogen Amics publicy listed? Yes, Dishman Carbogen Amics is a public company listed on BOM.
What is the stock symbol of Dishman Carbogen Amics? Dishman Carbogen Amics trades under 540701 ticker.
When did Dishman Carbogen Amics go public? Dishman Carbogen Amics went public in 2004.
Who are competitors of Dishman Carbogen Amics? Similar companies to Dishman Carbogen Amics include e.g. Jubilant Pharmova, Biocon, Syngene International, Suven Pharma.
What is the current market cap of Dishman Carbogen Amics? Dishman Carbogen Amics's current market cap is $391M
What is the current revenue growth of Dishman Carbogen Amics? Dishman Carbogen Amics revenue growth between 2023 and 2024 was 5%.
Is Dishman Carbogen Amics profitable? Yes, Dishman Carbogen Amics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.